Jaguar Health, Inc. (JAGX) Stock

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

Jaguar Health, Inc. is led by CEO Lisa A. Conte, employs 49 people, headquartered in US, publicly traded since 2015.

Jaguar Health, Inc. (JAGX) stock trades at $0.93 with a market capitalization of $61962. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of -0.04, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.91 and $92.75, and currently trades 99.0% below its 52-week high.

On profitability, Jaguar Health, Inc. generates a return on equity (ROE) of 764.53% — well above the market average, a sign of a high-quality business, return on capital employed of 784.29%, an operating margin of -383.33%, a net profit margin of -115.39%.

Official website: jaguar.health